Merck (MRK): Director bought ~$250K

~$250K

Approx. value · 2,832.86 sh @ $88.25

2,932.86

Holds after · shares reported

Traded

Feb 6, 2025

Filed

Feb 7, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 8, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
2. Dec 11, 2024FDAFDA drug approval: Keytruda
3. Jan 15, 2025Congress · 1 personMembers of Congress: 3 sales
4. Jan 16, 2025Congress · 1 personMembers of Congress: 2 sales
5. Jan 17, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
6. Jan 24, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
7. Jan 27, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
8. Jan 28, 2025FDAFDA drug approval: Keytruda
9. Feb 5, 2025InsiderDirector purchased ~$1.33M of MRK shares in the open market
10. Feb 6, 2025 · this disclosureInsiderDirector purchased ~$250K of MRK shares in the open market

What came next

1. Feb 6, 2025InsiderOfficer sold ~$210K of MRK shares in the open market
2. Feb 12, 2025Court · District Court, D. New JerseySecurities lawsuit filed: IN RE MERCK & CO., INC. SECURITIES LITIGATION
3. Feb 13, 2025InsiderOfficer sold ~$512K of MRK shares in the open market
4. Feb 19, 2025InsiderOfficer sold ~$715K of MRK shares in the open market
5. Feb 24, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
6. Feb 25, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
7. Feb 26, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
8. Mar 3, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
9. Mar 19, 2025FDAFDA drug approval: Keytruda
10. Mar 20, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
11. Mar 31, 2025CongressDisclosed partial sale of MRK — reported range $15,001 - $50,000
12. Apr 8, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
13. Apr 9, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
14. Apr 15, 2025FDAFDA drug approval: Welireg
15. Apr 15, 2025FDAFDA drug approval: Welireg
16. Apr 17, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
17. Apr 21, 2025FDAFDA drug approval: Keytruda
18. Apr 21, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
19. Apr 25, 2025InsiderOfficer sold ~$353K of MRK shares in the open market
20. Apr 29, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Merck

• SEC Form 144Nov 12, 2026
• SEC Form 144Nov 2, 2026
• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 24, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026

Everything OQRO holds on this company is on its MRK page.